Skip to main content

D.K. Pharmachem Pvt. Ltd.

Calcipotriol Anhydrous vs Monohydrate: Which Form Should Your Formulation Team Source?

Team DK Pharmachem By Team DK Pharmachem
October 1, 2026

Calcipotriol Anhydrous vs Monohydrate: Which Form Should Your Formulation Team Source? Table of Contents A purchase order for “Calcipotriol” looks simple. It is not. The same molecule is sold in two solid forms, anhydrous and monohydrate, and the choice affects potency calculations, stability behaviour, regulatory filings and supplier shortlisting. Teams that treat the two forms

Read More

How In-House Analytical Validations Reduce Supply Chain Risks in Contract Manufacturing

Team DK Pharmachem By Team DK Pharmachem
September 9, 2026

How In-House Analytical Validations Reduce Supply Chain Risks in Contract Manufacturing Table of Contents In contract manufacturing, supply chain risks can come from more than raw material shortages or production delays. Testing and quality activities can also affect timelines when important analytical work depends on external laboratories. For pharmaceutical manufacturers, having analytical capabilities in-house can

Read More

DMF vs CEP vs USDMF: A Guide for US Pharma Sourcing Teams Before Placing a Bulk API Order from India

Team DK Pharmachem By Team DK Pharmachem
August 29, 2026

DMF vs CEP vs USDMF: A Guide for US Pharma Sourcing Teams Before Placing a Bulk API Order from India Table of Contents If you’re a sourcing or regulatory affairs professional at a US pharmaceutical company evaluating an Indian bulk API supplier, you’ve likely run into three acronyms that get used loosely, and sometimes incorrectly:

Read More

How US Generic Drug Makers Can Qualify Indian API Manufacturers: A Pharma Sourcing Checklist

Team DK Pharmachem By Team DK Pharmachem
August 26, 2026

How US Generic Drug Makers Can Qualify Indian API Manufacturers: A Pharma Sourcing Checklist Table of Contents For a US generic drug maker, the decision to bring on a new Active Pharmaceutical Ingredient (API) supplier is rarely just a procurement exercise. It is a regulatory, quality, and business continuity decision that will affect an Abbreviated

Read More